Results 1 to 10 of about 115,182 (147)

Special Issue “Virus-Like Particle Vaccines” [PDF]

Viruses, 2020
Virus-like particles (VLPs) have become a key tool for vaccine developers and manufacturers [...]
Monique Vogel, Martin F. Bachmann
doaj   +4 more sources

Preclinical Development of a Novel Zika Virus-like Particle Vaccine in Combination with Tetravalent Dengue Virus-like Particle Vaccines [PDF]

Vaccines
Declared as a Public Health Emergency in 2016 by the World Health Organization (WHO), the Zika virus (ZIKV) continues to cause outbreaks that are linked to increased neurological complications.
Dominik A. Rothen, Sudip Kumar Dutta, Pascal S. Krenger, Alessandro Pardini, Anne-Cathrine S. Vogt, Romano Josi, Ilva Lieknina, Albert D. M. E. Osterhaus, Mona O. Mohsen, Monique Vogel, Byron Martina, Kaspars Tars, Martin F. Bachmann   +12 more
doaj   +2 more sources

Four nudivirus core genes present in the genome of Venturia canescens are required for virus-like particle formation and prevention of encapsulation of parasitoid wasp eggs [PDF]

Journal of Virology
Venturia canescens is a parasitoid wasp that harbors a domesticated endogenous virus (DEV) and parasitizes host insects like Ephestia kuehniella. The V. canescens DEV evolved from an alphanudivirus and produces virus-like particles (VLPs) in females that
Meng Mao, Corinne M. Stouthamer, Ange Lorenzi, Michael R. Strand, Gaelen R. Burke   +4 more
doaj   +2 more sources

Programmable polymorphism of a virus-like particle

Communications Materials, 2022
Virus-like particles are promising for drug delivery systems and vaccine development, but controlling their size and morphology is challenging. Here, amino acid sequences are inserted into MS2 bacteriophage virus-like particles, with their size and shape
Artur P. Biela, Antonina Naskalska, Farzad Fatehi, Reidun Twarock, Jonathan G. Heddle   +4 more
doaj   +1 more source

Zika virus-like particle (VLP) based vaccine. [PDF]

PLoS Neglected Tropical Diseases, 2017
The newly emerged mosquito-borne Zika virus poses a major public challenge due to its ability to cause significant birth defects and neurological disorders.
Hélène Boigard, Alexandra Alimova, George R Martin, Al Katz, Paul Gottlieb, Jose M Galarza   +5 more
doaj   +1 more source

Enhancing Anti-SARS-CoV-2 Neutralizing Immunity by Genetic Delivery of Enveloped Virus-like Particles Displaying SARS-CoV-2 Spikes

Vaccines, 2023
New vaccine delivery technologies, such as mRNA, have played a critical role in the rapid and efficient control of SARS-CoV-2, helping to end the COVID-19 pandemic.
Yongping Yang, Wing-Pui Kong, Cuiping Liu, Tracy J. Ruckwardt, Yaroslav Tsybovsky, Lingshu Wang, Shuishu Wang, Daniel W. Biner, Man Chen, Tracy Liu, Jonah Merriam, Adam S. Olia, Li Ou, Qi Qiu, Wei Shi, Tyler Stephens, Eun Sung Yang, Baoshan Zhang, Yi Zhang, Qiong Zhou, Reda Rawi, Richard A. Koup, John R. Mascola, Peter D. Kwong   +23 more
doaj   +1 more source

Development of Respiratory Syncytial Virus Vaccine Candidates for the Elderly

Viruses, 2023
Respiratory syncytial virus (RSV) is a significant threat to elderly populations and repeated infections that occur throughout life are poorly protective. To assess the role of prior RSV infections as well as elderly immune senescence on vaccine efficacy,
Jorge C. G. Blanco, Lori M. Cullen, Arash Kamali, Fatouomata Y. D. Sylla, Marina S. Boukhvalova, Trudy G. Morrison   +5 more
doaj   +1 more source

Cross-Protection Induced by Virus-like Particles Derived from the Influenza B Virus

Biomedicines, 2022
The mismatch between the circulating influenza B virus (IBV) and the vaccine strain contributes to the rapid emergence of IBV infection cases throughout the globe, which necessitates the development of effective vaccines conferring broad protection. Here,
Hae-Ji Kang, Ki-Back Chu, Keon-Woong Yoon, Gi-Deok Eom, Jie Mao, Fu-Shi Quan   +5 more
doaj   +1 more source

Advancing usability of an influenza hemagglutinin virus-like particle vaccine expressing a chimeric cytokine

Virology Journal, 2023
Vaccine efficacy of conventional influenza vaccines depend on the antigenic similarity between the selected vaccine strain and annual epidemic strain. Since the influenza virus evolves yearly, a vaccine which is independent from viral antigenic mutation ...
Toshifumi Imagawa, Youta Arasaki, Kenichi Maegawa, Shigeo Sugita, Kuniaki Nerome   +4 more
doaj   +1 more source

Virus-like Particle Vaccines and Platforms for Vaccine Development

Viruses, 2023
Virus-like particles (VLPs) have gained a lot of interest within the past two decades. The use of VLP-based vaccines to protect against three infectious agents—hepatitis B virus, human papillomavirus, and hepatitis E virus—has been approved; they are ...
Milad Kheirvari, Hong Liu, Ebenezer Tumban   +2 more
doaj   +1 more source